All In Biotech

Investigational drug · Phase 3

zeleciment basivarsen

Also called: DYNE-101

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

1

Any phase or sponsor naming "zeleciment basivarsen"

First trial start

2022

Sep 5, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "zeleciment basivarsen", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Myotonic Dystrophy Type 1 (DM1)
  • DM1
  • Myotonic Dystrophy
  • Steinert Disease
  • Steinert

Approved drugs for the same conditions: Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "zeleciment basivarsen" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 3 on PubMed

Also in development for Myotonic Dystrophy Type 1 (DM1)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.